Adcetris or brentuximab vedotin

Adcetris or brentuximab vedotin

Patient-friendly review of Brentuximab Vedotin which is a chemotherapy drug that belongs in the classification of monoclonal antibody and antineoplastic for the treatment of cHL (classical Hodgkin lymphoma) and ALCL (systemic anaplastic large cell lymphoma).

The new ’biologic’ drug made by Seattle Genetics was approved by the FDA in 2011. It targets lymphoma and costs roughly 9,000 pounds or $16,000 US a month. The mean increased survival time in research was 7 months. 

Adcetris consists of a drug and an antibody - an antibody-drug conjugate - the antibody directs the drug to CD30, a target on lymphoma cells. It was approved under the FDA’s accelerated approval programme. However the FDA approved Adcetris after evaluating a single-arm clinical trial with only 102 participants. Patients received only Adcetris. The human study’s endpoint was objective response rate - what percentage of participants’ tumours either shrank or disappeared altogether after treatment. 73% of them achieved either a partial or complete response and responded to therapy for 6.7 months (average).

The systemic ALCL single-arm clinical trial involved only 58 patients. They received only Adcetris. The primary endpoint was the same; Objective response rate. 86% of them achieved either a partial or complete response, and responded for 12.6 months (average).

An infusion of Brentuximab is given over 30 minutes. The dosage received can depend on other factors such as weight and the state of patient’s health.

Side effects seem the usual nausea, fatigue, white cell decline, upper respiratory infection and sickness.

Precautions:

Hematologic toxicities, peripheral neuropathy, severe infections and hepatotoxicity.

Damaging the embryo (embryo-fetal toxicity) if the medical drug is used during pregnancy.

 
Learn about your cancer drugs.
CancerAcitve Logo
Subscribe (Free e-Newsletter)

Join Our
Newsletter

Join Our Newsletter Signup today for free and be the first to get notified on new updates.